Raymond James Financial’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Raymond James Financial’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.23M	Sell	76,610 -63,814	-45%	-$1.85M	﹤0.01%	3275
2025 Q4	$3.68M	Sell	140,424 -7,683	-5%	-$198K	﹤0.01%	2753
2025 Q3	$3.5M	Buy	148,107 +12,552	+9%	+$278K	﹤0.01%	2732
2025 Q2	$2.78M	Buy	135,555 +10,314	+8%	+$208K	﹤0.01%	2813
2025 Q1	$2.57M	Buy	125,241 +96,973	+343%	+$2.16M	﹤0.01%	2818
2024 Q4	$640K	Buy	+28,268	New	+$679K	﹤0.01%	3752

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

Raymond James Financial's IDNA Position: Q1 2026 in Review

Raymond James Financial reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 45% in Q1 2026, selling an estimated $1.85M and leaving 76,610 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #3275.

Raymond James Financial first reported a position in IDNA in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.68M in Q4 2025. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

Raymond James Financial held 76,610 shares of iShares Genomics Immunology and Healthcare ETF worth $2.23M as of Q1 2026.
Raymond James Financial sold 63,814 iShares Genomics Immunology and Healthcare ETF shares in Q1 2026, an estimated $1.85M.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3275 holding.
Raymond James Financial first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's iShares Genomics Immunology and Healthcare ETF position peaked at $3.68M in Q4 2025.
60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.